Michal Sheleg, Ph.D.

Michal Sheleg, Ph.D.

Vice President, Clinical Development
Pluri
Michal Sheleg oversees clinical programs and regulatory strategy. She previously served as Pluri’s Medical Director. Sheleg earned her Ph.D. in Toxicology from the Rutgers University/University of Medicine and Dentistry of New Jersey.

Articles by Michal Sheleg, Ph.D.

  • Unlocking the potential of unconventional T cells

    Wednesday, June 25, 2025
    The cutting edge of cancer research is now expanding beyond conventional T cells to a less-explored, unconventional, unique subset of T cell: mucosal-associated invariant T (MAIT) cells. Engineered MAIT cells may stand to change future allogeneic treatments for solid tumors.